biotech
biotech Articles
Solid Bio shares were absolutely crushed on Tuesday after the firm announced that the FDA has placed its Ignite DMD Phase 1/2 study of SGT-001 on hold.
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The October 31 short interest data has been compared with the previous report, and short interest in...
Published:
NextCure updated clinical results from its early stage cancer study at the Society for Immunotherapy of Cancer annual meeting. As a result, NextCure shares were crushed on Monday.
Published:
Lipocine shares absolutely plummeted on Monday after the firm announced that it received a Complete Response Letter from the FDA regarding its New Drug Application for Tlando.
Published:
Nektar Therapeutics shares made a handy gain on Monday after the firm announced updated results from its first-in-human Phase 1a study of NKTR-358 for the treatment of autoimmune and other chronic...
Published:
Iovance Bio shares jumped on Friday after the firm announced results from its mid-stage metastatic melanoma study.
Published:
On a day that the Dow Jones industrials and S&P 500 just hit all-time highs, many companies are not exactly feeling the same love. Bluebird Bio is one such company.
Published:
Wright Medical Group shares exploded on Monday after it was announced that the firm would be acquired by Stryker.
Published:
Redhill Bio shares jumped early on Monday after the firm announced that the FDA approved Talicia for the treatment of Helicobacter pylori infection in adults.
Published:
Biogen and Alkermes have announced that the FDA approved Vumerity for the treatment of relapsing forms of multiple sclerosis.
Published:
When Amgen released its third-quarter financial results after the markets closed on Tuesday, the firm said that it had $3.66 in earnings per share (EPS) and $5.7 billion in revenue. That compared...
Published:
Amgen is set to report its most recent quarterly results after the closing bell on Tuesday. Wall Street expectations are muted.
Published:
Melinta shares dropped on Friday even though the firm announced that the FDA has approved Baxdela (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia.
Published:
The October 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
Eton Pharma shares jumped on Tuesday after the firm announced that the FDA has approved Biorphen for treatment of hypotension.
Published: